These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 36370191)

  • 61. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience.
    Angelopoulou MK; Vassilakopoulos TP; Batsis I; Sakellari I; Gkirkas K; Pappa V; Giannoulia P; Apostolidis I; Apostolopoulos C; Roussou P; Panayiotidis P; Dimou M; Kyrtsonis MC; Palassopoulou M; Vassilopoulos G; Moschogiannis M; Kalpadakis C; Margaritis D; Spyridonidis A; Michalis E; Anargyrou K; Repousis P; Hatzimichael E; Bousiou Z; Poulakidas E; Grentzelias D; Harhalakis N; Pangalis GA; Anagnostopoulos A; Tsirigotis P
    Hematol Oncol; 2018 Feb; 36(1):174-181. PubMed ID: 28219112
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.
    Chen R; Palmer JM; Martin P; Tsai N; Kim Y; Chen BT; Popplewell L; Siddiqi T; Thomas SH; Mott M; Sahebi F; Armenian S; Leonard J; Nademanee A; Forman SJ
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2136-2140. PubMed ID: 26211987
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Brentuximab vedotin and immune checkpoint inhibitors for the treatment of Hodgkin lymphoma].
    Maruyama D
    Rinsho Ketsueki; 2020; 61(8):890-900. PubMed ID: 32908053
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP.
    Driessen J; Kersten MJ; Visser L; van den Berg A; Tonino SH; Zijlstra JM; Lugtenburg PJ; Morschhauser F; Hutchings M; Amorim S; Gastinne T; Nijland M; Zwezerijnen GJC; Boellaard R; de Vet HCW; Arens AIJ; Valkema R; Liu RDK; Drees EEE; de Jong D; Plattel WJ; Diepstra A;
    Leukemia; 2022 Dec; 36(12):2853-2862. PubMed ID: 36241696
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults.
    Harker-Murray P; Mauz-Körholz C; Leblanc T; Mascarin M; Michel G; Cooper S; Beishuizen A; Leger KJ; Amoroso L; Buffardi S; Rigaud C; Hoppe BS; Lisano J; Francis S; Sacchi M; Cole PD; Drachtman RA; Kelly KM; Daw S
    Blood; 2023 Apr; 141(17):2075-2084. PubMed ID: 36564047
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party.
    Bazarbachi A; Boumendil A; Finel H; Mohty M; Castagna L; Peggs KS; Blaise D; Afanasyev B; Diez-Martin JL; Sierra J; Bloor A; Martinez C; Robinson S; Malladi R; El-Cheikh J; Corradini P; Montoto S; Dreger P; Sureda A
    Br J Haematol; 2018 Apr; 181(1):86-96. PubMed ID: 29468647
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Prolonged responses to brentuximab vedotin as last therapy in Hodgkin lymphoma failing autologous transplantation: A case series.
    Broccoli A; Argnani L; Coppola PE; Gentilini M; Bagnato G; Lolli G; Carella M; Nanni L; Morigi A; Casadei B; Pellegrini C; Stefoni V; Zinzani PL
    Tumori; 2023 Apr; 109(2):249-252. PubMed ID: 35441544
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective.
    Sureda A; André M; Borchmann P; da Silva MG; Gisselbrecht C; Vassilakopoulos TP; Zinzani PL; Walewski J
    BMC Cancer; 2020 Nov; 20(1):1088. PubMed ID: 33172440
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma.
    Zinzani PL; Ramchandren R; Santoro A; Paszkiewicz-Kozik E; Gasiorowski R; Johnson NA; de Oliveira JSR; Buccheri V; Perini GF; Dickinson M; McDonald A; Özcan M; Sekiguchi N; Zhu Y; Raut M; Saretsky TL; Nahar A; Kuruvilla J
    Blood Adv; 2022 Jan; 6(2):590-599. PubMed ID: 34644372
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Impact of Pretransplant Salvage Therapies on Outcome of Hodgkin Lymphoma Patients Performing Allogeneic Transplant.
    Fanelli F; Hohaus S; Cantonetti M; Cimino G; Pennese E; Battistini R; Galli E; Cerretti R; Proia A; Fatone F; Provenzano I; Abruzzese E; Finolezzi E; Pulsoni A; Rigacci L
    Chemotherapy; 2023; 68(3):131-137. PubMed ID: 36549287
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Brentuximab Vedotin Plus Ibrutinib in Relapsed and Refractory Hodgkin Lymphoma.
    Mei M; Tsai NC; Palmer J; Armenian S; Chen R; Rosen S; Forman S; Popplewell L; Kwak L; Martin P; Maddocks K; Bond D; Herrera AF
    Clin Lymphoma Myeloma Leuk; 2024 Aug; 24(8):537-542. PubMed ID: 38693037
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients.
    Uncu Ulu B; Dal MS; Yönal Hindilerden İ; Akay OM; Mehtap Ö; Büyükkurt N; Hindilerden F; Güneş AK; Yiğenoğlu TN; Başcı S; Kızıl Çakar M; Yanardağ Açık D; Korkmaz S; Ulaş T; Özet G; Ferhanoğlu B; Nalçacı M; Altuntaş F
    J Chemother; 2022 May; 34(3):190-198. PubMed ID: 34514960
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studies.
    Forero-Torres A; Fanale M; Advani R; Bartlett NL; Rosenblatt JD; Kennedy DA; Younes A
    Oncologist; 2012; 17(8):1073-80. PubMed ID: 22855426
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Peritransplant Radiation Therapy in Patients With Refractory or Relapsed Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant: Long-Term Results of a Retrospective Study of the Fondazione Italiana Linfomi.
    Levis M; Campbell BA; Matrone F; Grapulin L; Di Russo A; Buglione M; Iamundo De Cumis I; Simontacchi G; Ciammella P; Magli A; Pascale G; Meregalli S; MacManus M; Fanetti G; De Felice F; Furfaro G; Ciccone G; Ricardi U
    Int J Radiat Oncol Biol Phys; 2023 Aug; 116(5):1008-1018. PubMed ID: 36822373
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma.
    Ramsey SD; Nademanee A; Masszi T; Holowiecki J; Abidi M; Chen A; Stiff P; Viviani S; Sweetenham JW; Radford J; Zhu Y; Bonthapally V; Thomas E; Richhariya A; Hunder NN; Walewski J; Moskowitz CH
    Br J Haematol; 2016 Dec; 175(5):860-867. PubMed ID: 27649689
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma.
    Herrera AF; Moskowitz AJ; Bartlett NL; Vose JM; Ramchandren R; Feldman TA; LaCasce AS; Ansell SM; Moskowitz CH; Fenton K; Ogden CA; Taft D; Zhang Q; Kato K; Campbell M; Advani RH
    Blood; 2018 Mar; 131(11):1183-1194. PubMed ID: 29229594
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Brentuximab vedotin plus bendamustine versus platinum-based regimens as 1st salvage therapy and 'bridge' to autologous hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma.
    Kaloyannidis P; Al Zayer M; Al Darweesh M; Al Batran M; Al Garni A; Al Naim A; Al Hashmi H; Kanfar S
    Leuk Lymphoma; 2023 Mar; 64(3):742-745. PubMed ID: 36628991
    [No Abstract]   [Full Text] [Related]  

  • 78. Brentuximab vedotin and its use in the treatment of advanced Hodgkin's lymphoma.
    Nikolaenko L; Nademanee A
    Future Oncol; 2020 Oct; 16(29):2273-2282. PubMed ID: 32677451
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Where Do the New Drugs Fit in for Relapsed/Refractory Hodgkin Lymphoma?
    Khan N; Moskowitz AJ
    Curr Hematol Malig Rep; 2017 Jun; 12(3):227-233. PubMed ID: 28488185
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Potential Benefit of Involved-Field Radiotherapy for Patients With Relapsed-Refractory Hodgkin's Lymphoma With Incomplete Response Before Autologous Stem Cell Transplantation.
    Levis M; Piva C; Filippi AR; Botto B; Gavarotti P; Pregno P; Nicolosi M; Freilone R; Parvis G; Gottardi D; Vitolo U; Ricardi U
    Clin Lymphoma Myeloma Leuk; 2017 Jan; 17(1):14-22. PubMed ID: 27727134
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.